semaglutide and cardiovascular Evaluating the Benefits of Innovator 2.4 mg (Recombinant DNA (r-DNA)) in Patients With Overweight or Obesity: A Critical Review of Current Evidence Semaglutide Linked to Cardiovascular Gains,

A key mechanism of GLP-1 medications is slowing gastric emptyingthe rate at which food moves from the stomach into the small intestinewhich helps with blood glucose control and weight management

Injections are often neededdaily/ alternate days at first, then weekly or monthly

Foods 10(5):910

Phase 3 trials of CagriSema demonstrated: 15.6% body weight loss with the combination versus 8.1% with semaglutide alone Superior glycemic control compared to either component individually Manageable side effect profile with proper dose titration Regulatory submissions completed in 2024 for obesity treatment [6] Since retatrutide includes GLP-1 receptor activation (similar to semaglutide) plus additional GIP and glucagon receptor effects, the theoretical cagrilintide blend with retatrutide could potentially exceed even the impressive CagriSema results

A 2025 meta-analysis of randomised controlled trials found no signal